1,2-Bis(perfluorbutyl)ethan | 142083-52-1

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: 1,2-Bis(perfluorbutyl)ethan
• 英文别名: 5H,5H,6H,6H-octadecafluoro-decane；Decane, 1,1,1,2,2,3,3,4,4,7,7,8,8,9,9,10,10,10-octadecafluoro-；1,1,1,2,2,3,3,4,4,7,7,8,8,9,9,10,10,10-octadecafluorodecane
• CAS: 142083-52-1
• 化学式: C₁₀H₄F₁₈
• 分子量: 466.113
• InChiKey: XYTVKPCMDPOOFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  18

文献信息

• Novel diabetes imaging probes
  申请人：——

  公开号：US20030207823A1

  公开（公告）日：2003-11-06

  The present invention relates to novel imaging probes and methods for using the probes in diagnostic imaging processes and other imaging processes to determine physiological functions.

  本发明涉及新型成像探针以及使用这些探针在诊断成像过程和其他成像过程中确定生理功能的方法。
• Control of nitric oxide bioactivity by perfluorocarbons
  申请人：New York University

  公开号：US20040127425A1

  公开（公告）日：2004-07-01

  Perfluorocarbons are used to control nitric oxide metabolism, either to inhibit nitric oxide activity or to potentiate the effects of nitric oxide. Perfluorocarbons can be used, for example, to treat hypotension and vasoplegia in septic shock, to protect against myocardial ischemia-reperfusion injury, to treat hypertension, and to provide antiplatelet effects.
• METHODS AND COMPOSITIONS TO TREAT MYOCARDIAL CONDITIONS
  申请人：Michal Eugene T.

  公开号：US20100144635A1

  公开（公告）日：2010-06-10

  Methods, devices, kits and compositions to treat a myocardial infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle. In other embodiments, the method includes the introduction of structurally reinforcing agents. In other embodiments, agents are introduced into a ventricle to increase compliance of the ventricle. In an alternative embodiment, the prevention of remodeling includes the prevention of thinning of the ventricular infarct zone. In another embodiment, the prevention of remodeling and thinning of the infarct zone involves the cross-linking of collagen and prevention of collagen slipping. In other embodiments, the structurally reinforcing agent may be accompanied by other therapeutic agents. These agents may include but are not limited to pro-fibroblastic and angiogenic agents.
• US6911457B2
  申请人：——

  公开号：US6911457B2

  公开（公告）日：2005-06-28
• US7641643B2
  申请人：——

  公开号：US7641643B2

  公开（公告）日：2010-01-05